Compare ResMed Inc. (RMD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs 10X Genomics Inc — how do they compare? ResMed Inc. trades at $220 (market cap $32.61B), while 10X Genomics Inc trades at $59 (market cap $7.61B). The key difference: ResMed Inc. is far larger — about 4.3× 10X Genomics Inc's market cap, and ResMed Inc. pays a 1.17% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| RMD | TXG | |
|---|---|---|
Market Cap | $32.61B | $7.61B |
Sector | Health | Health |
52-Week High | $293.73 | $58.57 |
52-Week Low | $182.82 | $11.34 |
Enterprise Value | $31.97B | $7.14B |
Dividend Yield | 1.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
